AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
Category: #health  By Nikita Chaurasia  Date: 2019-02-22
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
  • The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial
  • Anti-Tau monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech

The Switzerland-based clinical-stage biopharmaceutical company AC Immune has reportedly declared that Genentech has commenced enrollment of patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, called as MTAU9937A, RO7105705, developed to treat moderate Alzheimer’s disease.

As per trusted sources, the same antibody is also being assessed by Genentech in a different Phase 2 trial to measure it safety and efficacy in patients with prodromal-to-mild Alzheimer's disease.

Chief Executive Officer of AC Immune, Professor Andrea Pfeifer was reportedly quoted saying that the company is highly encouraged owing to the fact the Genentech is expanding its clinical assessment of AC Immune’s anti-Tau antibody. The interest to target Tau was recently shown by the company’s newest collaboration with Eli Lilly which was formed in early January to develop small molecule Tau MorphomerTM to treat Alzheimer’s, Pfeifer further added.

Reportedly, these projects demonstrate the scientific leadership of AC Immune in the field and are a significant part of its broad portfolio of three product candidates in Phase 2 clinical testing, an increasingly visible focus on early projects targeting neuro-inflammation and neuro-orphan indications, and additional diagnostics in clinical development.

According to a press release by AC Immune, the development of the monoclonal antibody is an important aspect of the partnership the company formed with Genentech in the year 2012 to market the monoclonal humanized antibodies against Tau protein. Reportedly, the monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech.

For the record, Tau pathology spreads with a distinctive spatiotemporal pattern in the brain, coinciding with both disease progression and clinical symptoms in Alzheimer’s disease.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...